Financière de Tubize SAの収益YQ/Q
Financière de Tubize SAの収益YQ/Qは何ですか。
Financière de Tubize SAの収益YQ/Qは-100.00%です。
収益YQ/Qの定義は何ですか。
四半期収益成長率、前年比は、前年同期の業績と比較して、売上高の増加率がパーセンテージとして表されています。
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
EURONEXTのセクタHealth Careにおける収益YQ/Qの企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の収益yq/q
- Diamcor Miningの収益YQ/Qは-100.29%です。
- Jupiter European Opportunities Trust Plcの収益YQ/Qは-100.26%です。
- ICS Globalの収益YQ/Qは-100.22%です。
- Treasure ASAの収益YQ/Qは-100.10%です。
- Sentry Select Primary Metalsの収益YQ/Qは-100.06%です。
- Candy Clubの収益YQ/Qは-100.03%です。
- Financière de Tubize SAの収益YQ/Qは-100.00%です。
- Arcotechの収益YQ/Qは-99.99%です。
- Prime Mediaの収益YQ/Qは-99.99%です。
- Mineral Mountain Mining & Milling Coの収益YQ/Qは-99.98%です。
- Wonderla Holidaysの収益YQ/Qは-99.98%です。
- Sanwaria Consumerの収益YQ/Qは-99.97%です。
- Ezagooの収益YQ/Qは-99.95%です。